Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about JUNS, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Oxygen at 1.5 ATA (atmospheres absolute) | Traumatic Brain Injury | Phase 1/2 · NCT01847755 | Completed |
| Trans-Resveratrol | Parkinson's Disease | Phase 2 · NCT07592767 | Recruiting |
Also used in these trials (approved or third-party drugs, not JUNS's own candidates): Pimozide, Crisaborole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
JUNS holds $1.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.9M/quarter from operations, an estimated runway of 2.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Factors that could cause or contribute to these differences include, but are not limited to, those identified below and those discussed in the section titled Risk Factors in this filing and our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (the10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JUNS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JUNS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →